Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the grant of 15,175 restricted stock units to 15 newly hired non-executive officers. The awards were approved by the company's compensation committee and granted under the Ultragenyx Employment Inducement Plan on December 16, 2024. The stock units will vest over four years, with 25% vesting annually on each grant date anniversary, contingent on continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Ultragenyx Pharmaceutical (NASDAQ: RARE) ha annunciato l'assegnazione di 15.175 unità azionarie riservate a 15 nuovi dirigenti non esecutivi. I premi sono stati approvati dal comitato per la compensazione dell'azienda e concessi nell'ambito del Piano di Induzione all'Occupazione di Ultragenyx il 16 dicembre 2024. Le unità azionarie matureranno nell'arco di quattro anni, con il 25% che matura annualmente in corrispondenza dell'anniversario della data di assegnazione, a condizione di continuare a essere impiegati. Questa assegnazione è stata effettuata in conformità alla Regola di Quotazione Nasdaq 5635(c)(4) come incentivo all'occupazione.
Ultragenyx Pharmaceutical (NASDAQ: RARE) anunció la concesión de 15,175 unidades de acciones restringidas a 15 nuevos oficiales no ejecutivos. Las concesiones fueron aprobadas por el comité de compensación de la empresa y otorgadas bajo el Plan de Inducción de Empleo de Ultragenyx el 16 de diciembre de 2024. Las unidades de acciones se adquirirán durante cuatro años, con el 25% adquiriéndose anualmente en cada aniversario de la fecha de concesión, condicionado a la continuidad en el empleo. Esta concesión se realizó de acuerdo con la Regla de Listado de Nasdaq 5635(c)(4) como un incentivo laboral.
울트라제닉스 제약(Ultragenyx Pharmaceutical, NASDAQ: RARE)은 15명의 신입 비상임 임원에게 15,175개의 제한 주식 단위를 부여한다고 발표했습니다. 이 상은 회사의 보상 위원회에 의해 승인되었으며 2024년 12월 16일에 울트라제닉스 고용 유도 계획에 따라 부여되었습니다. 주식 단위는 4년에 걸쳐 분할 지급됩니다, 매년 부여 날짜 기념일에 25%가 지급되며, 지속적인 고용 조건이 필요합니다. 이 부여는 고용 유도를 위해 Nasdaq 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
Ultragenyx Pharmaceutical (NASDAQ: RARE) a annoncé l'octroi de 15 175 unités d'actions restreintes à 15 nouveaux cadres non exécutifs. Les prix ont été approuvés par le comité de rémunération de l'entreprise et ont été accordés dans le cadre du Plan d'Induction à l'Emploi d'Ultragenyx le 16 décembre 2024. Les unités d'actions vigeront sur quatre ans, avec 25 % de l'attribution prenant effet chaque année à l'anniversaire de la date de l'attribution, sous réserve de l'emploi continu. Cet octroi a été réalisé conformément à la Règle d'Inscription du Nasdaq 5635(c)(4) comme incitation à l'emploi.
Ultragenyx Pharmaceutical (NASDAQ: RARE) gab die Vergabe von 15.175 beschränkten Aktieneinheiten an 15 neu eingestellte nicht-executive Führungskräfte bekannt. Die Auszeichnungen wurden vom Vergütungsausschuss des Unternehmens genehmigt und im Rahmen des Ultragenyx Employment Inducement Plans am 16. Dezember 2024 gewährt. Die Aktieneinheiten werden über vier Jahre erwerben, wobei jährlich am Jahrestag der Gewährung 25% fällig werden, vorausgesetzt, die Beschäftigung dauert an. Diese Vergabe erfolgte gemäß der Nasdaq-Notierungsregel 5635(c)(4) als Beschäftigungsanreiz.
- None.
- None.
NOVATO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 15,175 restricted stock units of the company’s common stock to 15 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of December 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
FAQ
How many restricted stock units did Ultragenyx (RARE) grant in December 2024?
What is the vesting schedule for Ultragenyx's (RARE) December 2024 restricted stock units?
Under which plan were the Ultragenyx (RARE) December 2024 stock units granted?
How many new non-executive officers received Ultragenyx (RARE) restricted stock units in December 2024?
